Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.160
Buy
RSI(14)
52.242
Neutral
STOCH(KDJ)(9,3,3)
43.155
Sell
ATR(14)
13.702
Low Volatility
CCI(14)
-18.320
Neutral
Williams %R
63.897
Sell
TRIX(12,20)
0.224
Sell
StochRSI(14)
0.000
Oversold
Regeneron Pharmaceuticals Inc
REGNView Detailed Chart
554.580USD
-3.565-0.64%
Close 07/30, 16:00（ET）Quotes delayed by 15 min
60.01BMarket Cap
13.34P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.64%
5 Days
-3.11%
1 Month
+5.63%
6 Months
-18.81%
Year to Date
-22.15%
1 Year
-48.55%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
28
analysts
BUY
Current Rating
730.837
Target Price
30.94%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
172
Total
5
Median
8
Average
Company name
Ratings
Analysts
Regeneron Pharmaceuticals Inc
REGN
28
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
33
Amgen Inc
AMGN
33
Gilead Sciences Inc
GILD
30
1
2
3
...
35
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Sell
Moving Average
Indicators
Value
Direction
MA5
559.819
Sell
MA10
557.047
Sell
MA20
554.899
Sell
MA50
543.037
Buy
MA100
576.241
Sell
MA200
670.444
Sell
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Ticker SymbolREGN
CompanyRegeneron Pharmaceuticals Inc
CEODr. Leonard S. Schleifer, M.D., Ph.D
Websitehttps://www.regeneron.com/
Related Instruments
-0.38%
-0.51%
-1.00%
+3.53%
-0.50%
-1.06%
-7.25%
-0.72%
+0.46%
-2.02%
-0.20%
+0.16%
-1.88%
+0.39%
-1.73%
+3.45%
-1.46%
+2.80%
+0.32%
-5.03%
